Protocol Ledger

NCT04545515 · Phase III · COMPLETED

A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes

Interventional Phase III clinical trial protocol NCT04545515 sponsored by Vertex Pharmaceuticals in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-01-11 Enrollment: 120 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04545515
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)120 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04545515
Protocol FieldVerified Registry Value
NCT IdentifierNCT04545515
Consolidated Lead SponsorVertex Pharmaceuticals
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment120 participants (ACTUAL)
Registered Start Date2021-01-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04545515
Hospital Research SiteLocationSite Profile
Queensland Children's HospitalSouth Brisbane, AustraliaOpen Hospital Dossier ->
The Children's Hospital at WestmeadWestmead, AustraliaOpen Hospital Dossier ->
The Hospital for Sick ChildrenToronto, CanadaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Vertex Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI